200 related articles for article (PubMed ID: 30985947)
1. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
[TBL] [Abstract][Full Text] [Related]
2. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Salmon M; White HE; Zizkova H; Gottschalk A; Motlova E; Cerveira N; Colomer D; Coriu D; Franke GN; Gottardi E; Izzo B; Jurcek T; Lion T; Schäfer V; Venturi C; Vigneri P; Zawada M; Zuna J; Hovorkova L; Koblihova J; Klamova H; Markova MS; Srbova D; Benesova A; Polivkova V; Zackova D; Mayer J; Roeder I; Glauche I; Ernst T; Hochhaus A; Polakova KM; Cross NCP
Leukemia; 2022 Jul; 36(7):1879-1886. PubMed ID: 35676453
[TBL] [Abstract][Full Text] [Related]
3. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
4. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Hanfstein B; Lauseker M; Hehlmann R; Saussele S; Erben P; Dietz C; Fabarius A; Proetel U; Schnittger S; Haferlach C; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
Haematologica; 2014 Sep; 99(9):1441-7. PubMed ID: 24837466
[TBL] [Abstract][Full Text] [Related]
5. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
6. Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM; Claudiani S; O'Hare M; Szydlo R; Gerrard G; Foskett P; Foroni L; Milojkovic D; Apperley JF; Khorashad J
Br J Haematol; 2022 Apr; 197(1):52-62. PubMed ID: 34997766
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
8. Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Pagnano KBB; Miranda EC; Delamain MT; Duarte GO; de Paula EV; Lorand-Metze I; de Souza CA
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):728-733. PubMed ID: 28822797
[TBL] [Abstract][Full Text] [Related]
9. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
Ercaliskan A; Eskazan AE
Cancer; 2018 Oct; 124(19):3806-3818. PubMed ID: 29694669
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Lucas CM; Harris RJ; Giannoudis A; Davies A; Knight K; Watmough SJ; Wang L; Clark RE
Haematologica; 2009 Oct; 94(10):1362-7. PubMed ID: 19713230
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
[TBL] [Abstract][Full Text] [Related]
13. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
[TBL] [Abstract][Full Text] [Related]
14. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
15. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
Auewarakul CU; Huang S; Yimyam M; Boonmoh S
Acta Haematol; 2006; 116(2):114-9. PubMed ID: 16914906
[TBL] [Abstract][Full Text] [Related]
16. Distribution of
Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
[TBL] [Abstract][Full Text] [Related]
17. "Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key?
Bernardi S; Bonifacio M; Iurlo A; Zanaglio C; Tiribelli M; Binotto G; Abruzzese E; Russo D
Eur J Haematol; 2019 Sep; 103(3):272-273. PubMed ID: 31233644
[No Abstract] [Full Text] [Related]
18. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
Su YJ; Kuo MC; Chen TY; Wang MC; Yang Y; Ma MC; Lin TL; Lin TH; Chang H; Teng CJ; Hsiao PC; Chen CC; Wang PN; Shih LY
Cancer Sci; 2022 Oct; 113(10):3518-3527. PubMed ID: 35869805
[TBL] [Abstract][Full Text] [Related]
19. The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the
Stella S; Gottardi EM; Favout V; Barragan Gonzalez E; Errichiello S; Vitale SR; Fava C; Luciano L; Stagno F; Grimaldi F; Pironi L; Sargas Simarro C; Vigneri P; Izzo B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817063
[TBL] [Abstract][Full Text] [Related]
20. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.
Martinez RJ; Kang Q; Nennig D; Bailey NG; Brown NA; Betz BL; Tewari M; Thyagarajan B; Bachanova V; Mroz P
Arch Pathol Lab Med; 2022 Jan; 146(1):92-100. PubMed ID: 33769465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]